Fact CheckerSign in

NCT05500443Completed

The DANish COronary DEcalcification (DANCODE) Trial

The Effects of Menaquinone-7 Supplementation in Patients With Severe Coronary Calcifications

Source: ClinicalTrials.gov · Last updated 26 Aug 2026

Brief summary (registry, in English)

1\. Abstract Introduction Coronary artery calcification (CAC) and especially progression in CAC is a strong predictor of acute myocardial infarction and cardiovascular mortality. A substudy in the recent Danish study, AVADEC, suggested a protective role of supplementation with vitamin K2 and D in the development of CAC. This finding should be interpreted with caution, but the perspective is very interesting. In this study, we will examine the effect of the supplementation on progression of CAC in men and women with severe CAC. We hypothesize that the supplementation will slow down the calcification process. Method and analysis In this multicenter and double-blinded placebo-controlled study, 400 men and women with CAC score ≥ 400 are randomized (1:1) to treatment with vitamin K2 (720 µg/day) and vitamin D (25 µg/day) or placebo treatment (no active treatment) for two years. Exclusion criteria are treatment with vitamin K antagonist or coagulation disorders. To evaluate CAC score, a non-contrast CT-scan is performed at baseline and repeated after 12 and 24 months of follow-up. Primary outcome is difference in CAC score from baseline to follow-up at two years. Intention-to-treat principle is used for all analyses. Ethics and dissemination There are no reported adverse effects associated with the use of vitamin K2. Prior to inclusion, the protocol will be approved by the Regional Scientific Ethical Committee for Southern Denmark and the Data Protection Agency. It will be conducted in accordance with the Declaration of Helsinki. Positive as well as negative findings will be reported.

Status (registry)
Completed
Study type
Interventional
Enrollment
400 (actual)
First submitted
11 Aug 2022
Start date
Feb 2023
Primary completion date
Jul 2026
Lead sponsor
Odense University Hospital
NCT number
NCT05500443

What you commit to

  • Study type: Interventional
  • Participants enrolled: 400
  • From Feb 2023 to the primary completion date, Jul 2026
  • 3 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • History of myocardial infarction or coronary revascularization
  • History of venous thrombosis including pulmonary embolism
  • Coagulation disorders

Lab values

  • Disorders of calcium and phosphate metabolism (as primary hyperparathyroidism)

Age

  • Women of childbearing age (due to radiation issues)
  • A life-expectancy \< 5 years

Other

  • Vitamin K antagonist use

Who the study is looking for

  • Coronary artery calcium (CAC) score above 400

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (3)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Department of Cardiology, Odense University Hospital
Coordinator of this site? Confirm its status
OdenseDenmarkUnknown status
Department of Cardiology
Coordinator of this site? Confirm its status
SvendborgDenmarkUnknown status
Department of Cardiology
Coordinator of this site? Confirm its status
VejleDenmarkUnknown status

Related publications

This page is information, not medical advice. Discuss any trial with your doctor.